CompletedPhase 4

Mortality Reduction After Oral Azithromycin Contingency: Mortality Study

United States, Niger66,228 participantsStarted 2017-10-20

Plain-language summary

MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently treated with mass azithromycin for one year. The present trial re-randomized communities to azithromycin or placebo for the fourth and fifth year of the study.

Who can participate

Age range1 Month – 60 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Communities- All communities eligible for MORDOR (NCT02047981) * Individuals-All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census Exclusion Criteria: * Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

What they're measuring

All-cause Mortality Rate in Children Aged 1-60 Months

Timeframe: 24 months

Macrolide Resistance in Children Aged 1-60 Months

Timeframe: 18 months

Normalized Macrolide Resistance in Children Aged 1-60 Months

Timeframe: 18 months

Trial details

NCT IDNCT03338244

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-07-31

Results submitted2022-03-23

View on ClinicalTrials.gov More Childhood Mortality trials